Leo International Precision Health Aktiengesellschaft: management transactions · Germany · BaFin

About Leo International Precision Health Aktiengesellschaft

Leo International Precision Health Aktiengesellschaft (ISIN DE0005490601, ticker LEOW.DE) is a German-listed company trading on Xetra/Frankfurt (DAX/MDAX/SDAX), with its market presence effectively on the Frankfurt Stock Exchange’s General Standard segment. The company is incorporated in Germany, with operational headquarters in Planegg/Martinsried near Munich, while corporate registry and governance information also reference Düsseldorf. Formerly known as SPOBAG Aktiengesellschaft, the company was transformed through a reverse takeover into a publicly listed precision-health platform focused on artificial intelligence. Today, Leo International Precision Health AG operates as an investment and holding company building an integrated AI-driven healthcare ecosystem. Its strategic scope spans biotech, MedTech, HealthTech and healthcare services. Rather than functioning as a single-product drug developer, the group is designed as a platform owner and consolidator: it acquires, holds and develops complementary healthcare assets, then seeks to create value through portfolio integration, operational alignment and cross-asset synergies. According to company disclosures, the investment case is centered on combining technology, data, operations and capital to accelerate the monetization of innovative healthcare assets. From a business-line perspective, the company’s activities are mainly investment-led: ownership of portfolio companies, strategic development, licensing and management of intellectual property, and the build-out of an ecosystem around precision health. The official messaging indicates exposure to AI-enabled healthcare businesses, which may include software, digital health solutions, medical technology, research and development capabilities, and related commercial services. Importantly, the company is still in an early formation stage: its 2025 results state that the consolidated group structure was created only at the end of 2025 and that six portfolio companies were first consolidated during that period, leaving limited historical operating comparability. In competitive terms, Leo International Precision Health AG aims to position itself as a capitalized consolidation vehicle in a fragmented and fast-evolving precision medicine and healthcare technology market. Its potential advantages include access to the German capital markets, a listed structure, and a strategy built around acquiring and integrating assets rather than relying on a single technology platform. However, the investment profile also carries significant execution risk, including integration complexity, ongoing financing needs, and regulatory exposure across healthcare, data and intellectual-property domains. Recent highlights are material. In December 2025, the company completed the acquisition of its first six holdings through a capital increase in kind. In April 2026, it published its 2025 annual results, confirming that the group had laid the strategic foundation for its AI-driven precision-health platform and signaling continued portfolio expansion and integration work in 2026. For international investors, LEOW.DE is therefore best understood as an emerging German-listed health-and-AI platform with early-stage operating visibility, a consolidator strategy, and a potentially attractive but still highly developmental risk-return profile.